1st Quarter - Report — CEPHEID for CEPHEID (2013)

Firm

CEPHEID

Client

CEPHEID

Income

—

Expenses

$70,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

See page threeLobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues

Lobbyist	Covered position, as disclosed
HALLIE CHRISTINE LEWIS	—
MICHELE M SCHOONMAKER	—

Contacted: Natl Institutes of Health (NIH); Food & Drug Administration (FDA); SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES; Agency for Healthcare Research & Quality (AHRQ); Centers For Disease Control & Prevention (CDC)

Medicare/Medicaid MMM

See page 7Lobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues

Lobbyist	Covered position, as disclosed
HALLIE CHRISTINE LEWIS	—
MICHELE M SCHOONMAKER	—

Contacted: Agency for Healthcare Research & Quality (AHRQ); Food & Drug Administration (FDA); Medicare Payment Advisory Commission (MedPAC); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); SENATE; Centers For Medicare and Medicaid Services (CMS)

Medical/Disease Research/Clinical Labs MED

See page fiveLobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues

Lobbyist	Covered position, as disclosed
HALLIE CHRISTINE LEWIS	—
MICHELE M SCHOONMAKER	—

Contacted: Natl Institutes of Health (NIH); Medicare Payment Advisory Commission (MedPAC); Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); SENATE; Agency for Healthcare Research & Quality (AHRQ); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.